Media Contact:
Stephen Majors
Vice President, Global Communications
smajors@alliancerm.org
Washington, DC
ARM applauds the HHS announcement that the Center for Medicare and Medicaid Innovation (CMMI) will test a “Cell and Gene Therapy Access Model” to administer multi-state outcomes-based agreements in Medicaid programs for transformative cell and gene therapies.
Washington, D.C.
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy sector, announced the appointment of Mark Battaglini to the newly created position of Chief Strategy Officer, effective today.
Brussels
The European Union can reverse its declining competitiveness and ensure patient access to transformative treatments if it modernizes its policy and regulatory framework to reflect the distinct promise of cell and gene therapies as the future of medicine, the Alliance for Regenerative Medicine (ARM) will say during an event at the EU Parliament on 29 November.
Carlsbad, CA
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2023 Officers, Executive Committee, and Board of Directors.
